These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 33328215)

  • 1. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
    Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
    Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.
    Chokshi CR; Shaikh MV; Brakel B; Rossotti MA; Tieu D; Maich W; Anand A; Chafe SC; Zhai K; Suk Y; Kieliszek AM; Miletic P; Mikolajewicz N; Chen D; McNicol JD; Chan K; Tong AHY; Kuhlmann L; Liu L; Alizada Z; Mobilio D; Tatari N; Savage N; Aghaei N; Grewal S; Puri A; Subapanditha M; McKenna D; Ignatchenko V; Salamoun JM; Kwiecien JM; Wipf P; Sharlow ER; Provias JP; Lu JQ; Lazo JS; Kislinger T; Lu Y; Brown KR; Venugopal C; Henry KA; Moffat J; Singh SK
    Nat Med; 2024 Oct; 30(10):2936-2946. PubMed ID: 39095594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
    Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
    J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.
    Chen C; Jing W; Chen Y; Wang G; Abdalla M; Gao L; Han M; Shi C; Li A; Sun P; Jiang X; Yang Z; Zhang S; Zhang J; Tang C; Liu Y; Zhang R; Xu F; Dong B; Li X; Liu M; Qiang B; Sun Y; Wei X; Li J; Hu Q; Jiang X
    Sci Transl Med; 2022 Aug; 14(656):eabn1128. PubMed ID: 35921473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells.
    Qiu Z; Zhao L; Shen JZ; Liang Z; Wu Q; Yang K; Min L; Gimple RC; Yang Q; Bhargava S; Jin C; Kim C; Hinz D; Dixit D; Bernatchez JA; Prager BC; Zhang G; Dong Z; Lv D; Wang X; Kim LJY; Zhu Z; Jones KA; Zheng Y; Wang X; Siqueira-Neto JL; Chavez L; Fu XD; Spruck C; Rich JN
    Cancer Discov; 2022 Feb; 12(2):502-521. PubMed ID: 34615656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products.
    Logun M; Colonna MB; Mueller KP; Ventarapragada D; Rodier R; Tondepu C; Piscopo NJ; Das A; Chvatal S; Hayes HB; Capitini CM; Brat DJ; Kotanchek T; Edison AS; Saha K; Karumbaiah L
    Cytotherapy; 2023 Jun; 25(6):670-682. PubMed ID: 36849306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the alpha
    Cobb DA; de Rossi J; Liu L; An E; Lee DW
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
    Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
    Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
    Choi SI; Yin J
    Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.
    Tang N; Cheng C; Zhang X; Qiao M; Li N; Mu W; Wei XF; Han W; Wang H
    JCI Insight; 2020 Feb; 5(4):. PubMed ID: 31999649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
    Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
    Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
    Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
    Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.